Pharma and diagnostics are fast becoming stronger, independent verticals supporting healthcare services across the world. Molecular technology is advancing in a big way and nanotechnology is the next major thing to redefine rapid testing and early diagnosis. Pharmaceutical companies are also reinventing themselves by embracing nanotechnology and investing in R&D. Where does India stand to benefit from these advances and can these be scaled to a mass level?